Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the United Kingdom by Verganti, S et al.
  
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is the peer reviewed version of the following article, which has been published in final form 
at http://dx.doi.org/10.1111/jsap.12613. 
Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G. A., Elders, R., 
Doyle, R., Taylor, A. and Murphy, S. (2017), Use of Oncept melanoma vaccine in 69 
canine oral malignant melanomas in the UK. J Small Anim Pract, 58: 10–16.  
This article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Self-Archiving. 
The full details of the published version of the article are as follows: 
 
TITLE: Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK 
AUTHORS: Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G. A., Elders, R., 
Doyle, R., Taylor, A. and Murphy, S. 
JOURNAL TITLE: Journal of Small Animal Practice 
PUBLISHER: Wiley, for British Small Animal Veterinary Association 
PUBLICATION DATE: 17 January 2017 (online) 
DOI: 10.1111/jsap.12613  
Use of OnceptTM melanoma vaccine in 74 canine oral malignant melanomas in the United Kingdom 
 
 
S. Verganti1, D. Berlato1, L. Blackwood2, I. Amores-Fuster2, G. A. Polton3, R. Elders1, R. Doyle4 &, A. Taylor5, S. 
Murphy1 
 
1. Animal Health Trust, Kentford, Newmarket CB8 7UU 
2. School of Veterinary Science, University of Liverpool, Liverpool, Merseyside L3 5DA 
3. North Downs Specialist Referrals, Bletchingley, Redhill RH1 4QP 
4. Davies Veterinary Specialists, Higham Gobion, Hitchin SG5 3HR 
5. The Royal Veterinary College, Kings Cross, London NW1 0TU 
 
Corresponding author email: sara.verganti@aht.org.uk  
 
 
 
Keywords – canine, melanoma, oral, treatment, vaccine 
 
  
Summary 1 
 2 
Objectives  –  Oral  malignant  melanomas  (OMM)  carry  a  poor-to-guarded   prognosis,  due  to  local 3 
invasiveness and high metastatic propensity. The OnceptTM melanoma vaccine is licensed to treat dogs 4 
with stage II or III locally-controlled OMM. The aim of this retrospective study was to assess survival of 5 
dogs with OMM treated with the vaccine in the UK. 6 
 7 
Methods – Medical records of dogs with histopathologically-confirmed OMM that received at least four 8 
doses of the vaccine were evaluated. Survival analyses for potential prognostic factors were performed. 9 
 10 
Results  – Seventy-four  dogs  were  included.  Thirty-seven dogs died of causes attributable to OMM; 11 
median survival time (MST) was 455 days (95% CI, 313-597). Based on Kaplan-Meier survival analysis 12 
with associated log-rank testing, age (<9 years; p<0.001), pigmentation (<50% pigmented cells; p=0.02) 13 
and WHO stage (p=0.03) were statistically significant prognostic factors. In a multivariate model, only 14 
age maintained significance (p=0.01). Eight of thirteen patients with macroscopic disease showed clinical 15 
response. 16 
 17 
Clinical significance – The patients treated with the melanoma vaccine in our study had MSTs similar to 18 
dogs with OMM receiving the vaccine in the USA.  Subpopulations of dogs with significantly varied 19 
responses to the vaccine were identified. Response of patients with macroscopic disease was seen. 20 
  21 
Introduction 22 
Melanoma is the most common malignant tumour of the oral cavity in dogs (Ramos-Vara et al. 2000, Smith 23 
et al. 2002). It usually exhibits aggressive local behaviour and high, early metastatic potential, especially to 24 
regional lymph nodes and lungs (Bostock 1979, Modiano et al. 1999). However, individual tumour behaviour 25 
can vary, as a wide range of survival times has been described (Ottnod et al. 2013). Furthermore, a 26 
proportion of oral tumours are well-differentiated histologically and carry a good prognosis after surgery 27 
alone (Spangler & Kass 2006, Esplin 2008). 28 
 29 
For untreated dogs with oral malignant melanoma (OMM), death due to progressive disease (PD) and/or 30 
metastases occurs after a median time of 2 months (Harvey et al. 1981). Following conventional treatments 31 
[surgery, radiation therapy (RT) and/or chemotherapy], median survival times (MST) range from 4·8 to 12 32 
months (Kosovsky et al. 1991, Wallace et al. 1992, Bateman et al. 1994, Blackwood & Dobson 1996, Théon et 33 
al. 1997, Freeman et al. 2003, Proulx et al. 2003, Murphy et al. 2005, Boston et al. 2014). Surgery and RT are 34 
effective at achieving local tumour control, and curative-intent surgery has recently been associated with 35 
prolonged survival (Tuohy et al. 2014). 36 
 37 
Nevertheless, metastatic disease is a common cause of death for patients with OMM (Blackwood & Dobson 38 
1996, Théon et al. 1997, Murphy et al. 2005). Several studies evaluating the use of conventional 39 
chemotherapy in the adjuvant setting have failed to demonstrate a substantial survival benefit (Rassnick et 40 
al. 2001, Proulx et al. 2003, Murphy et al. 2005, Brockley et al. 2013, Dank et al. 2014). 41 
 42 
Melanoma is a highly immunogenic tumour (Modiano et al. 1999). The Oncept vaccine (Merial, Duluth, GA, 43 
USA) contains plasmid DNA-targeting tyrosinase, a glycoprotein essential for melanin synthesis and 44 
demonstrated to be overexpressed in melanomas (Bergman & Wolchok 2008). Following promising phase I 45 
trial results (Bergman et al. 2003), the vaccine received conditional licensure from the United States 46 
Department of Agriculture in 2007 for treatment of stages II/III, locoregionally controlled canine OMMs. In a 47 
prospective clinical trial of 58 dogs with stage II/III locoregionally controlled OMM, the use of the vaccine 48 
significantly increased survival times compared to historical controls (Grosenbaugh et al. 2011). A 49 
retrospective study failed to demonstrate a survival advantage with the use of the vaccine in a similar 50 
population of dogs (Ottnod et al. 2013). Following USA licensure, the melanoma vaccine has been used in 51 
several UK referral centres to treat dogs with OMM. Recently, a retrospective study of 32 UK-based dogs 52 
with stages I to III OMM treated with the melanoma vaccine showed a MST of 355 days; no prognostic 53 
factors were identified (Treggiari et al. 2016). Nevertheless, the overall data reporting field use remain 54 
sparse. The aims of this retrospective study were to assess survival times of dogs with OMM treated with the 55 
melanoma vaccine in UK and to identify possible prognostic factors that might influence survival, and to 56 
describe the use of melanoma vaccine in patients with macroscopic disease. 57 
 58 
Materials and Methods 59 
Animals 60 
Medical records for dogs with OMM that were presented to five UK referral centres from January 2009 to 61 
December 2012 were reviewed (January 2009 is the date the melanoma vaccine became available in the UK). 62 
Inclusion criteria were histological and/or immunohistochemical diagnosis of OMM and dogs that received 63 
the melanoma vaccine as part of the treatment. Dogs diagnosed with well-differentiated oral melanoma or 64 
melanoma involving the haired portion of the lip were excluded from the study because of the more 65 
favourable prognosis associated with these types compared to those of the oral cavity or involving the 66 
mucosal aspect of the lip (Esplin 2008, Smedley et al. 2011). Patients were also excluded if incompletely 67 
staged. 68 
 69 
The following information were collected for each dog: signalment, date of diagnosis, tumour size and site 70 
within the oral cavity, lymph node status, staging performed, completeness of -locoregional control achieved 71 
immediately prior to vaccination [defined as no gross evidence at the excision site and, in cases of metastatic 72 
regional lymph node(s), treatment of the lymph node(s) with surgery or RT prior to vaccination]. The initial 73 
vaccination dates, number of vaccine doses, adverse effects, and other treatments apart from the vaccine 74 
were also recorded. The following information was retrieved from the histopathology reports: percentage of 75 
pigmented neoplastic cells, mitotic index (MI) and extent of surgical margins. Surgical margins were 76 
considered complete if the narrowest histologic margin was >2 mm. Dogs were staged according to the 77 
World Health Organisation tumour, node, metastases (TNM) guidelines (Table 1). For dogs with macroscopic 78 
disease, response was retrospectively assessed according to the response evaluation criteria in solid tumours 79 
(RECIST) (Nguyen et al. 2015). The vaccine was administered using the Vetjet transdermal device according 80 
to the manufacturer's instructions as previously described (Grosenbaugh et al. 2011). The “induction course” 81 
consisted of four doses 14 days apart; a booster vaccination was administered approximately every six 82 
months. Minor variations in vaccination schedule occurred to meet clients’ needs. Information regarding 83 
cause of death and presence/absence of macroscopic or metastatic disease for patients alive at the end of 84 
the study were assessed clinically and/or via diagnostic imaging by either the primary or referral clinician and 85 
collected when available. 86 
 87 
Data analysis 88 
The primary outcome measures were overall survival (OS), defined as the time from date of surgery until 89 
date of death or euthanasia, and disease-free interval (DFI), defined as the time from surgery to recurrence 90 
or development of metastatic disease or death. An event was defined as death or euthanasia attributed to 91 
OMM. Dogs were classified as censored if they died or were euthanased due to unrelated causes, were alive 92 
at the end of the study or were lost to follow-up. Variables examined to determine their effect on OS 93 
included MI [<4/10 high powered fields (hpfs) vs ≥4/10 hpfs], percentage of pigmentation by histopathology 94 
(<50% pigmented neoplastic cells vs ≥50%), margins of excision (complete vs incomplete), WHO stage and 95 
regional lymph node status (metastatic vs non-metastatic). Lymph nodes that were normal in size but not 96 
sampled were considered non-metastatic in the statistical analysis. Kaplan-Meier product-limit estimation 97 
was used to estimate OS plots for potential categorical risk factors, and log-rank testing was used to compare 98 
survival impact of categorical variables. Values of P<0·05 were considered significant. Statistical analysis was 99 
performed using commercial software (IBM SPSS Statistics version 20·0). Statistical analysis was performed 100 
for patients with locoregional control prior to vaccination (stages I to III), while dogs with macroscopic 101 
disease were considered separately. Due to the low number of patients in the latter group, Kaplan-Meier 102 
product-limit estimation was used to estimate only OS plot. 103 
 104 
Results 105 
Sixty-nine dogs met the inclusion criteria; 56 patients had locoregional tumour control prior to vaccination 106 
while 13 dogs had macroscopic disease. The median age for the entire population was 10·9 years (range 5·2 107 
to 15·4 years). Patient signalment, clinical stage, treatments received and achievement of locoregional 108 
tumour control prior to vaccine are shown in Table 2. Histopathology reports were available for review in 67 109 
cases. Fifty-nine tumours (88·1%) had MI ≥4/10 hpfs (median 35·0/10 hpfs, range 4 to 150/10 hpfs) and 24 110 
(35·8%) had <50% pigmented cells. Table 3 indicates details of the RT protocols and chemotherapy 111 
treatments administered. 112 
In 13 cases the melanoma vaccine was used in the presence of macroscopic disease. Eight dogs had tumour 113 
recurrence after surgery (±RT), and concurrent regional lymph node involvement was found in three of 114 
these. Three of these eight patients concurrently received non-steroidal anti-inflammatory drugs (NSAIDs) 115 
and one received RT. Of the remaining dogs, the vaccine was used as palliative treatment for distant gross 116 
metastatic disease (three cases) and for the primary tumour after incisional biopsy (one case). In one dog the 117 
vaccine was initiated prior to surgery. Patients in the macroscopic group were staged as follows: four for 118 
stage I and three each for stages II to IV. 119 
 120 
Three hundred and seven doses of the melanoma vaccine were administered (mean 4·5, median 4) 121 
beginning at a median of 42 days after diagnosis (range 4 to 409 days). Most dogs (76·8%) received four 122 
doses of the vaccine; 16 (23·2%) dogs had one to five booster vaccinations (mean 1·9, median 1). All patients 123 
completed the induction course of the vaccine. However, one dog in the macroscopic group had PD after 124 
starting the vaccine, at which point surgery was performed. The vaccine was restarted after surgery and the 125 
treatment was completed. Adverse effects suspected to be related to the vaccine were reported in 12 dogs 126 
(17·4%) and included: pain at injection site (4), lethargy (2), local erythema (2), focal hair discolouration (2) 127 
and one each of lethargy and anorexia, subcutaneous haemorrhage at injection site and restlessness. Most 128 
of the adverse effects were temporary (<48 hours) and reported after the first or second vaccination; none 129 
were described following boosters. Additionally, one dog developed a squamous cell carcinoma (SCC) at the 130 
vaccination site. 131 
Outcomes 132 
At the time of analysis, 50% (28/56) of dogs with stages I to III OMM had died or were euthanased for causes 133 
attributable to OMM: 10 (17·9%) because of local recurrence at the surgical or RT site (five had concurrent 134 
involvement of the regional lymph node) and 16 (28·6%) due to metastasis (including regional lymph nodes, 135 
lungs, liver, brain, tonsil and skin), and two of unknown causes (but assumed to be melanoma-related by 136 
clinical determination). The MST for dogs staged I to III was 455 days (95% CI: 324 to 586 days; Fig 1) and the 137 
median DFI was 222 days (95% CI: 175 to 269 days; Fig 2). The MST from start of vaccination was 422 days 138 
(95% CI: 255 to 589 days). 139 
Eight dogs (14·3%) staged I to III survived less than 6 months; 62·5% of these had <50% pigmented neoplastic 140 
cells. Eleven dogs (19·6%) experienced long-term survival (615 to 1070 days), six of which were still alive at 141 
the end of the study. Of these 11 patients, eight had a melanotic tumour and three amelanotic. In eight dogs 142 
complete margins were achieved. Three of the eleven long-term survivors had stage I disease, five stage II 143 
and three stage III at initial presentation; six had surgery before the vaccine, four had surgery + RT (three 144 
before and one after the induction course of the vaccine) and one surgery + chemotherapy. 145 
In the censored group, 22 dogs (39·3%) were alive and 18 were free of detectable disease (11 cases based on 146 
clinical examination; for the other seven patients, diagnostic imaging confirmed remission). Of the remaining 147 
four dogs, three had documented local recurrence (in two patients there was also regional lymph node 148 
involvement) and one dog had suspected pulmonary metastases by CT. Of the 18 dogs considered disease-149 
free, nine staged I, four staged II and five staged III at initial presentation. Median follow-up time for 150 
censored dogs was 300 days (range 72 to 1070 days). One dog was lost to follow-up 615 days after initial 151 
diagnosis and considered free of detectable disease based on diagnostic imaging findings. Six dogs died or 152 
were euthanased due to causes other than OMM (10·7%), including second malignancy (multi-centric 153 
lymphoma, osteosarcoma, haemangiosarcoma), gastric dilation/volvulus, pulmonary-thromboembolism and 154 
hyperadrenocorticism. 155 
A Kaplan-Meier survival plot and associated log-rank test suggested that MI (P=0·47), degree of 156 
pigmentation (P=0·09), margins (P=0·27), WHO stage (P=0·19) and lymph node status (P=0·68) were not 157 
statistically-significant prognostic factors. 158 
Of the 13 patients with macroscopic disease at the time of first vaccination, three dogs achieved complete 159 
response (CR) of the primary tumour during the vaccine induction course. Two of these patients did not 160 
receive any other treatment and developed local recurrence 125 days and 139 days after the first 161 
vaccination; the third dog received firocoxib and had no evidence of local recurrence based on clinical 162 
examination 232 days after the first vaccination. One patient with local disease and involvement of the 163 
regional lymph node prior to vaccine had a partial response (PR) during the induction course but CR was 164 
described at the time of the first booster vaccination; this dog was receiving meloxicam and was alive and 165 
considered disease-free based on clinical examination 232 days after the first vaccination. A PR was seen in 166 
another dog though the tumour was also treated with RT at the same time. Of three dogs with stable disease 167 
(SD), one was receiving meloxicam and had PD after 164 days; the other two were treated with the vaccine 168 
only and the disease considered stable at last follow-up. The rest of the patients, including all stage IV 169 
melanomas, had PD. The MST for patients in the macroscopic group was 179 days from diagnosis (95% CI: 95 170 
to 263 days; Fig 3). The three patients with stage IV melanoma survived 171, 178 and 288 days from 171 
diagnosis, and 129, 130 and 241 days from the vaccination. None of these patients received other type of 172 
treatments, apart from surgery and melanoma vaccine. 173 
Discussion 174 
The purpose of this study was to retrospectively evaluate the survival times of dogs with OMM in the UK 175 
treated with the melanoma vaccine and to possibly identify associated prognostic factors for response. An 176 
additional aim was to describe the response of patients with macroscopic disease to the vaccine. 177 
The Oncept vaccine has been used to treat canine melanoma in UK referral centres after acquiring 178 
conditional FDA licensing in 2007 but publications evaluating effectiveness are limited. Furthermore, the two 179 
largest studies assessing the vaccine efficacy reported contrasting results (Grosenbaugh et al. 2011, Ottnod 180 
et al. 2013). The overall MST described in our study (455 days) for patients with stages I to III disease, was 181 
similar to that described by Ottnod et al. (2013) in which MST for vaccinated dogs was 477 vs 491 days for 182 
historical “controls”. However, our study included 14 patients (25%) with stage I disease which may have 183 
positively impacted survival compared to studies in which the vaccine was used for stages II and III OMMs 184 
only. Conversely, if we compare our data to those from a recent UK study including stages I to III (Treggiari et 185 
al. 2016), improved survival was achieved in this study. 186 
The degree of pigmentation of canine melanoma has been associated with survival in some studies (Esplin 187 
2008, Bergin et al. 2011); however, others have failed to demonstrate any correlation (Harvey et al. 1981, 188 
Hahn et al. 1994, Ramos-Vara et al. 2000). Although not statistically significant in our study population the 189 
MST for tumours with ≥50% pigmented neoplastic cells was 508 days compared to 310 days for tumours 190 
with <50% pigmented neoplastic cells. Our results support the idea that less pigmented tumours might be 191 
clinically more aggressive but this notion requires further formal testing in larger case series. 192 
In our population of dogs with stages I to III OMM, complete surgical margins were achieved in 13 patients 193 
(23·2%). Only 19 dogs (44·1%) with incomplete margins received adjuvant radiation therapy. Completeness 194 
of excision was not a statistically significant prognostic factor in our study. This is similar to results described 195 
by Grosenbaugh et al. (2011) and Ottnod et al. (2013), in which margins of excision did not correlate with 196 
survival. Nevertheless, for our patients with complete margins the MST was not reached and the mean 197 
survival was 628 days (95% CI: 388 to 869 days) compared to a MST of 417 days [95% CI: 266 to 568 days; 198 
mean 477 days (95% CI: 378 to 575 days)] for patients with incomplete margins. The lack of significance seen 199 
in this study could again be due to type II error or to the lack of histopathology review for confirmation of 200 
the margins of excision. 201 
In our study, WHO stage was not statistically significantly associated with survival (P=0·19). However, for 202 
patients with stage I disease the MST was not reached while the mean survival was 687 days (95% CI: 462 to 203 
912 days). Interestingly, dogs with stage II disease had a shorter MST compared to patients with stage III 204 
disease [269 days (95% CI: 118 to 421 days) and 342 days (95% CI: 214 to 470 days), respectively]. Several 205 
factors could have contributed to this. For example, 10/22 dogs with stage II disease had amelanotic 206 
tumours (45·4%) vs 5/20 (25%) patients with stage III disease. Furthermore, complete margins were 207 
achieved in 20% of staged III patients vs 9% of the dogs with staged II tumours. In regards to other treatment 208 
modalities (e.g. RT and chemotherapy) and time of delayed vaccination, these were similar for both groups. 209 
If we compare our results to the recent UK study on the melanoma vaccine (Treggiari et al. 2016), our stage 210 
II population experienced shorter survival while dogs with stages I and III disease had increased survival. 211 
Both studies are retrospective in nature and several confounding factors may have contributed to these 212 
results. Additionally, the dogs in this study received a combination of treatment modalities including surgery, 213 
RT, chemotherapy and NSAIDs. Based on the small number of patients for each subgroup, no statistical 214 
analysis was performed to assess the influence of different treatments on survival. However, it is not 215 
possible to exclude the potential role of chemotherapy and NSAIDs on tumour control. COX-2 expression has 216 
in fact been demonstrated in canine melanoma tissue, particularly in aggressive OMMs (Pires et al. 2010). 217 
Nevertheless, two previous studies (Boria et al. 2004, Murphy et al. 2005) showed that the use of NSAIDs for 218 
canine melanomas did not confer a biological response or survival advantage. 219 
Interestingly, in our study, 50% of patients with stages I to III disease died due to local recurrence (with or 220 
without regional lymph node involvement; 17·9%) or due to metastatic disease (29·6%); lymph nodes, lungs, 221 
liver, brain, tonsil and skin, were the described metastatic sites. This suggests that the melanoma vaccine 222 
may not be effective in all the patients treated or that its effect may be temporary. 223 
Eleven dogs (19·6%) staged I to III experienced long-term survival (615 to 1070 days), six of which were still 224 
alive at the end of the study. Several factors may have contributed to this result, including the presence of 225 
pigmented tumours in eight patients as well the achievement of complete margins for most of them (72·7%). 226 
As previously described by Hahn et al. (1994) and Proulx et al. (2003), regional lymph node metastasis did 227 
not appear to impact survival in our study population. However, seven patients with palpably normal lymph 228 
nodes did not have lymph node sampling performed at initial staging. This may have underestimated the 229 
number of cases with regional lymph node involvement, as up to 40% of normal lymph nodes are metastatic 230 
(Williams & Packer 2003). Nevertheless, none of the patients developed detectable lymph node metastases 231 
during the study period. 232 
The time between diagnosis and vaccination was extremely variable in our study (4 to 409 days). This was 233 
due to the fact that the melanoma vaccine was not available in the UK before 2009. The median time of first 234 
vaccination was 43 days after surgery (range 4 to 364 days) for patients with stages I to III disease, and 33 235 
days (range 11 to 409 days) for dogs in the macroscopic group. Most of the dogs with stages I to III tumours 236 
(71·4%) received the first dose of the melanoma vaccine within 2 months from diagnosis. Although there are 237 
no clear guidelines about when to start the vaccine, an early vaccination is recommended in order to give 238 
time to mount an immune response. Therefore, the delayed vaccination may have negatively influenced the 239 
outcome of some of our patients. Nevertheless, patients that received the vaccine at later stage may have 240 
also had less aggressive tumours. No statistical analysis was performed as to whether delayed vaccination 241 
was a significant prognostic factor in our population; however, the MSTs of stages I to III patients from 242 
diagnosis and vaccination were similar (455 days and 422 days, respectively). 243 
The melanoma vaccine was well-tolerated. Minimal adverse effects were described by owners, most being 244 
mild and self-limiting; the frequency of adverse reactions declined throughout the vaccination course. One 245 
dog developed SCC in the area of the vaccination site nine months after the first vaccine diagnosed using 246 
cytology. It is unclear whether this was related to the vaccine. 247 
 248 
The effect of the vaccine on macroscopic disease was described for the first time in this paper. Overall, eight 249 
of 13 patients showed clinical response. However, four of these patients had received other forms of 250 
treatment concurrent with the vaccine, including RT (one) and NSAIDs (three dogs). The overall response 251 
rate of the nine patients with macroscopic disease treated with the vaccine only was 44·4%. Of the four 252 
responders, two had CR and two had SD. It is interesting that in three dogs, response was documented 253 
during the induction course of the vaccine. The early response seen in this study was unexpected as a 254 
humoral response is reportedly detected within three to nine months after completion of the induction 255 
course of the melanoma vaccine (Liao et al. 2006). In our population it seems that some patients were able 256 
to develop a much more rapid response. Nevertheless, in most cases, the response was short-lasting (<4·5 257 
months). 258 
Three patients with stage IV disease treated with surgery and vaccine only survived between 5·6 and 9·5 259 
months from the initial diagnosis. Although these patients developed eventually -progressive disease, it is 260 
not possible to exclude that the vaccine had a potential role in slowing disease progression. Based on this 261 
preliminary data and the tolerability of the treatment, the melanoma vaccine could be considered as 262 
palliative treatment in patients with macroscopic disease, when surgery or radiotherapy is not an option, or 263 
for patients with advanced disease (i.e. stage IV). However, the response seen was extremely variable and 264 
further studies are required to investigate the role of the vaccine in the macroscopic setting. 265 
Due to its retrospective nature, there are several limitations in this study. Necropsy was not performed in 266 
any dogs; the attributed cause of death was often based on clinical examination by the referring or referral 267 
veterinarian and standard diagnostic procedures. Histopathology records were not available for two dogs 268 
and tumour samples were not reviewed, so variation between pathologists regarding histologic features of 269 
malignancy might exist. There was no control group, which limited the possibility of assessing the effect of 270 
the vaccine on survival. Additionally, the limited number of dogs in some subcategories might have 271 
introduced bias. Finally, cases were managed by multiple investigators and treatment type and time of 272 
vaccine initiation varied. 273 
In conclusion, our study dogs with OMM treated with the Oncept melanoma vaccine showed similar MSTs to 274 
those reported by Ottnod et al. (2013). In addition, our stage III patients had improved survival compared to 275 
a recent UK study on dogs treated with the vaccine (Treggiari et al. 2016). However, considering the 276 
limitations of this study, the lack of a control group and the different treatment modalities used for each 277 
patient, it is not clear whether the vaccine resulted in a survival advantage in our population. None of the 278 
prognostic factors analysed in the present study was statistically significant. Although this could be a genuine 279 
result, it is not possible to exclude type II error, based on the low number of patients in each subcategory 280 
and on the limitations of a retrospective study. 281 
Nevertheless, this is the first study that describes the use of the vaccine in dogs with macroscopic disease. 282 
Patients with macroscopic disease had a 44·4% response rate to the vaccine and the MST for dogs with stage 283 
IV disease was 178 days. Therefore, given its very good tolerability, the melanoma vaccine may be 284 
considered as palliative treatment for patients with advanced disease (e.g. stage IV) or for dogs with 285 
macroscopic tumours when other treatment modalities are not an option. 286 
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Table 1. World Health Organisation staging system for dogs with OMM 403 
Clinical stage 
 
I. Tumour < 2 cm diameter 
II. Tumour 2-4 cm diameter 
III. Tumour > 4 cm diameter and/or 
evidence of regional lymph node 
involvement 
IV. Any tumour size, any lymph node 
status, evidence of distant 
metastasis 
 404 
Table 2. Characteristics of the 69 dogs with OMM treated with the melanoma vaccine 405 
Category Variable n (%) 
Breed Purebreed 
Golden retriever 
Labrador retriever 
Flat-coated retriever 
Mixed breed 
51 (68.9%) 
16 (21.6%) 
6 (8.1%) 
1 (1.4%) 
23 (31.1%) 
Gender Male 
Neutered 
Entire 
Female 
Spayed 
Entire 
53 (71.6%) 
34 (46%) 
19 (25.7%) 
21 (28.4%) 
18 (24.3%) 
3 (4%) 
Location Gingival 
Maxillary 
Mandibular 
Labial (mucosal aspect) 
Lingual 
Hard palatal 
Oropharyngeal 
 
24 (32.4%) 
19 (25.7%) 
21 (28.4%) 
5 (6.8%) 
3 (4%) 
2 (2.7%) 
Investigations 
performed 
Physical examination 
Blood tests 
Thoracic radiography 
CT scan 
Thorax 
Abdomen 
Abdominal ultrasonography 
Regional lymph node assessment 
Cytology 
Histopathology 
74 (100%) 
63 (85.1%) 
55 (74.3%) 
 
34 (45.9%) 
16 (21.6%) 
18 (24.3%) 
62 (83.8%) 
55 (88.7%) 
13 (21%) 
Clinical stage I II 
III 
IV 
Unknown 
18 (24.3%) 
24 (32.4%) 
23 (31.1%) 
3 (4%) 
6 (8.1%) 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
Table 3. Radiation therapy protocols and chemotherapy treatments for the 69 patients with OMM 417 
Radiation  therapy n (%) Chemotherapy/TKI treatment n (%) 
Patients treated 
 
Type of treatment 
Adjuvant to surgery 
Main treatment 
At local recurrence 
 
In relation to melanoma vaccine 
Pre-vaccine 
Concurrent to vaccine 
Post-vaccine 
 
Protocol 
4 fractions x 8 Gy 
4 fractions x 8.5 Gy 
4 fractions x 9 Gy 
 
Treatment of regional lymph node 
Prophylactic 
Metastatic lymph node/s 
24 (32.4%) 
 
 
 
20 (27.0%) 
2 (2.7%) 
2 (2.7%) 
 
 
 
12 (16.2%) 
10 (13.5%) 
2 (2.7%) 
 
 
 
18 (24.3%) 
1 (1.4%) 
5 (6.8%) 
 
18 (24.3%) 
13 (17.6%) 
5 (6.8%) 
Patients treated 
 
Type of treatment 
Adjuvant to surgery and/or RT 
At local recurrence 
 
In relation to melanoma vaccine 
Pre-vaccine 
Concurrent to vaccine 
Post-vaccine 
 
Protocol 
Carboplatin 
Carboplatin and mitoxantrone 
Metronomic chlorambucil/NSAIDs 
Metronomic CXP/NSAIDs 
Toceranib phosphate 
13 (17.6%) 
 
 
 
6 (8.1%) 
7 (9.5%) 
 
 
 
6 (8.1%) 
4 (5.4%) 
11 (14.9%) 
 
 
 
5 (6.8%) 
1 (1.4%) 
3 (4.0%) 
4 (5.4%) 
2 (2.7%) 
 418 
  419 
Treatment modality Surgery 
Complete margins 
Incomplete margins 
Radiation therapy 
Primary site 
Primary site and local lymph nodes 
Systemic treatment 
NSAIDs 
Chemotherapy 
Toceranib phosphate 
74 (100%)
18 (24.3%) 
56 (75.7%) 
24 (32.4%) 
6 (8.1%) 
18 (24.3%) 
28 (37.8%) 
18 (24.3%) 
11 (14.9%) 
2 (2.7%) 
Local tumour control 
prior to vaccine 
Yes 
No 
Residual primary mass 
Regional lymph nodes 
Lungs 
61 (82.4%) 
13 (17.6%) 
7 (9.5%) 
6 (8.1%) 
3 (4.1%) 
Figure 1. Kaplan-Meier plot showing the median survival time of the 56 patients with locoregional control 420 
prior to vaccination (stages I to III). The overall median survival time was 455 days (95% CI, 324 to 586 days). 421 
Crosses represent censored observations. 422 
 423 
 424 
  425 
Figure 2. Kaplan-Meier plot showing the disease-free interval of the 56 patients with locoregional control 426 
prior to vaccination (stages I to III). The overall disease-free interval was 222 days (95% CI, 175 to 269 days). 427 
Crosses represent censored observations. 428 
 429 
  430 
Figure 3. Kaplan-Meier plot showing the median survival time of the 13 patients with macroscopic disease 431 
prior to vaccination. The overall median survival time was 178 days (95% CI, 95 to 263 days). Crosses 432 
represent censored observations. 433 
 434 
